Loading...

ELAN ELANCO ANIMAL HEALTH INC Product Launches 8-K Filing

LNC

LN

ELANCO ANIMAL HEALTH INC

(ELAN)

2024 8-K

Show Summary

Summary

Debt Restructuring

Earnings Report

Investor Conference

Board Appointment

Earnings Report

Term Loan Agreement

Financial Results

Completion of Asset Sale

Credit Agreement Amendment

Board Changes and Amendment...

Quantitative Data

Cooperation Agreement and B...

Merger of Equals

Asset Purchase Agreement

Investor Conferences

Leadership Changes and Voti...

Filing with Quantitative Data

Loan Agreement with Rabobank

Approval of Employee Stock ...

Financial Results Announcement

Financial Results Announcement

Presentation and FDA Submis...

External Links:

Elanco Animal Health presented a study on their JAK inhibitor, Zenrelia, at a symposium, showing no serious adverse events in dogs treated with it, and announced its approval in Canada.

AI Assistant

ELANCO ANIMAL HEALTH INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.